ATEA PHARMACEUTICALS INC (AVIR)

Company Profile

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The firm is engaged in developing its product candidate, bemnifosbuvir, for the treatment of coronavirus disease 2019 (COVID-19), and its variants. The firm is also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV). The bemnifosbuvir (AT-527) for COVID-19 addresses key limitations of current therapies and explores combination therapy for specific patient populations. Bemnifosbuvir is an investigational, orally administered, non-mutagenic, non-teratogenic, direct-acting antiviral agent. The firm's SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy but also explores the effect of combination therapy in a smaller sub-set of patients who receive an antiviral drug along with bemnifosbuvir.

Company Info

ATEA PHARMACEUTICALS INC

225 Franklin Street, Suite 2100

Boston MASSACHUSETTS 02110

P: 18572048109

CEO: Jean-Pierre Sommadossi

Employees: 74

Website: https://ateapharma.com/